The invention relates to high purity (1R,2S,4R)-(-)-2-[(2'-{N,N-dimethylamino}-ethoxy)]-2-[phenyl]-1,7,7-tri-[m ethyl]-bicyclo[2.2.1]heptane and pharmaceutically acceptable acid addition salts thereof containing not more than 0.2% of (1R,3S,4R)-3-[(2'-{N,N-dimethylamino}-ethyl)]-1,7,7-tri-[methyl]-bicyclo[2 .2.1]heptane-2-one and/or of a pharmaceutically acceptable acid addition salt thereof. Furthermore the invention is concerned with a process for the preparation of these compounds. Moreover the invention relates to medicaments containing 1 or more of these compounds and their use.

L'invention concerne la grande pureté (le 1R, le 2S, le 4R)-(-)-2-[(2'-{N, le N-dimethylamino}-ethoxy)]-2-[phenyl]-1, 7, le 7-tri-[m ethyl]-bicyclo[2.2.1]heptane et pharmaceutiquement addition acide acceptable sale contenir en pas plus de 0.2% de (1R, 3S, 4R)-3-[(2'-{N, N-dimethylamino}-ethyl)]-1, 7, 2.1]heptane-2-one 7-tri-[methyl]-bicyclo[2 et/ou d'un sel pharmaceutiquement acceptable d'addition acide en. En outre l'invention est concernée par un procédé pour la préparation de ces composés. D'ailleurs l'invention concerne des médicaments contenant 1 ou plus de ces composés et de leur utilisation.